INSIGHT: How Avastin Is Beating Erbitux In China Assistance Programs
This article was originally published in PharmAsia News
Executive Summary
Despite both having patient assistance programs (PAPs) for years, Roche’s Avastin leads Merck Serono’s Erbitux by a large margin in China, and the gap could be widening with a new program from Roche, notes a new report from Datamonitor.